Get the Stockscreener App
0.75
2.58%
-0.0199
After Hours:
.7501
0.000100
+0.01%
Spruce Biosciences Inc stock is currently priced at $0.75, with a 24-hour trading volume of 601.91K.
It has seen a -2.58% decreased in the last 24 hours and a +6.20% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.7737 pivot point. If it approaches the $0.7473 support level, significant changes may occur.
Previous Close:
$0.7699
Open:
$0.7527
24h Volume:
601.91K
Market Cap:
$30.87M
Revenue:
-
Net Income/Loss:
$-49.11M
P/E Ratio:
-0.4491
EPS:
-1.67
Net Cash Flow:
$-33.81M
1W Performance:
-9.93%
1M Performance:
+6.20%
6M Performance:
-44.44%
1Y Performance:
-67.39%
1D Range:
$0.7388
$0.7689
52W Range:
$0.6711
$5.95
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
415 655 4168
Address
2001 Junipero Serra Boulevard, Suite 640, Daly City
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
HC Wainwright & Co. Reiterates Spruce Biosciences (SPRB) Buy Recommendation - MSN
MSN
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
A company insider recently sold 465021 shares of Spruce Biosciences Inc [SPRB]. Should You Sale? – Knox Daily - Knox Daily
Knox Daily
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Spruce Biosciences Inc Stock (SPRB) Financials Data
Spruce Biosciences Inc (SPRB) Net Income 2024
SPRB net income (TTM) was -$49.11 million for the quarter ending September 30, 2023, a -11.07% decrease year-over-year.
Spruce Biosciences Inc (SPRB) Cash Flow 2024
SPRB recorded a free cash flow (TTM) of -$33.81 million for the quarter ending September 30, 2023, a +14.96% increase year-over-year.
Spruce Biosciences Inc (SPRB) Earnings per Share 2024
SPRB earnings per share (TTM) was -$1.49 for the quarter ending September 30, 2023, a +20.74% growth year-over-year.
About Spruce Biosciences Inc
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
0.77%
1.20%
Cap:
|
Volume (24h):